Moderna, INC Form 4 insider transactions

Moderna's President, Stephen Hoge, reports the vesting of performance-based restricted stock units and subsequent tax withholding.

Moderna's CEO, Stephane Bancel, reported the vesting of performance-based restricted stock units and the subsequent withholding of shares to cover tax obligations.

Stephen Hoge, President of Moderna, reports the vesting of restricted stock units and subsequent tax withholding, resulting in changes to his beneficial ownership of company stock.

Chief Financial Officer of Moderna, James Mock, reports the acquisition and disposal of company stock and restricted stock units on January 3, 2025.

Moderna's Chief Legal Officer, Shannon Klinger, acquired and disposed of company stock, including shares to cover tax obligations related to vesting restricted stock units.

Moderna's Chief Financial Officer, James Mock, was granted 188,761 restricted stock units that vest over time.

Moderna's Chief Legal Officer, Shannon Klinger, received 188,761 restricted stock units that will vest over time.

Moderna's Chief Legal Officer, Shannon Klinger, engaged in stock transactions involving the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Moderna's President, Stephen Hoge, executed stock transactions involving the vesting of restricted stock units and a sale to cover tax obligations.

Moderna's Chief Financial Officer, James Mock, engaged in multiple stock transactions, including the vesting of performance and restricted stock units and a sale to cover tax obligations, as detailed in a recent SEC filing.

Moderna's Chief Legal Officer, Shannon Klinger, engaged in stock transactions involving the vesting of restricted stock units and subsequent sales to cover tax obligations.

Moderna's President, Stephen Hoge, executed stock transactions involving the vesting of restricted stock units and sales to cover tax obligations.

Moderna's President, Stephen Hoge, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Chief Financial Officer of Moderna, James Mock, reports the acquisition and disposal of company stock, including transactions to cover tax obligations related to vesting restricted stock units.

Director Abbas Hussain acquired stock options and restricted stock units in Moderna, Inc. on October 2, 2024.

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported the acquisition and disposal of company stock, including transactions related to restricted stock units.

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported the acquisition and disposal of company stock, including transactions to cover tax obligations related to vesting restricted stock units.

Moderna's President, Stephen Hoge, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Chief Financial Officer of Moderna, James Mock, reports the acquisition and disposal of company stock, including transactions to cover tax obligations related to vesting restricted stock units.

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported the acquisition and disposal of company stock, including transactions to cover tax obligations related to vesting restricted stock units.

Moderna's President, Stephen Hoge, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Moderna's Chief Financial Officer, James Mock, recently engaged in transactions involving the vesting of performance and restricted stock units, followed by a sale of shares to cover tax obligations.

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported the acquisition and disposal of company stock, including transactions to cover tax withholding obligations.

Moderna's President, Stephen Hoge, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Director David M. Rubenstein reports acquisition of Moderna stock options and restricted stock units, set to vest in the coming years.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on July 31, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on July 24, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on July 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Moderna's President, Stephen Hoge, sold 15,000 shares of common stock at a price of $121.12 per share on July 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on July 10, 2024, under a pre-arranged Rule 10b5-1 trading plan.